Jason Shaoyun Xiang, Winchester, MA US

Patent application number

Description

Published

20080311113

METHOD FOR TREATING ADAMTS-5-ASSOCIATED DISEASE - The present invention relates to methods of treating ADAMTS-5-associated diseases and particularly osteoarthritis comprising administering an agent capable of modulating ADMATS-5 activity to a subject afflicted with the disease. The agent is preferably a biaryl sulfonamide compound. The invention is based, in part, on the discovery that transgenic animals that do not express functional ADAMTS-5 show a reduction in the degree of osteoarthritis after the induction of osteoarthritis as compared to WT animals. Furthermore, the ADAMTS-5 transgenic animals have reduced aggrecanase activity in articular tissue as compared to WT animals. These animals are good models for ADAMTS-5-associated diseases, and for screening of drugs useful in the treatment and/or prevention of these diseases. There are no other animal models in which the deletion of the activity of a single gene is capable of abrogating the course of osteoarthritis. Accordingly, these animals also show that osteoarthritis can be prevented and/or treated by administering to a subject an ADAMTS-5 inhibitory agent and particularly an agent capable of inhibiting the aggrecanase activity of ADAMTS-5.

Jie Xiang, Cambridge, MA US

Jing Xiang, Acton, MA US

Patent application number

Description

Published

20100278045

METHOD FOR MAINTAINING DIFFERENTIATED SERVICES DATA FLOW AT A NETWORK DEVICE IMPLEMENTING REDUNDANT PACKET DISCARD SECURITY TECHNIQUES - An improved method is described for providing Differentiated Services (Diffserv) traffic to a node in a network that implements a security method that discards duplicate packets received at the node. The method includes the step of identifying at least two service levels to be provided to received traffic and assigning different size look-back window counts to each of the service levels. The look-back window count indicates a number of packets that have been previously received at the node that should be compared against a received packet to determine whether a duplicate packet has been received. In one embodiment, a service level that has higher priority is assigned a lower look-back window count and thus examines fewer previously received packets than a service level having a lower priority. Such an arrangement reduces the possibility that traffic having higher priority is dropped as a security measure.

11-04-2010

20140269316

METHOD FOR MAINTAINING DIFFERENTIATED SERVICES DATA FLOW AT A NETWORK DEVICE IMPLEMENTING REDUNDANT PACKET DISCARD SECURITY TECHNIQUES - An improved method is described for providing Differentiated Services (Diffserv) traffic to a node in a network that implements a security method that discards duplicate packets received at the node. The method includes the step of identifying at least two service levels to be provided to received traffic and assigning different size look-back window counts to each of the service levels. The look-back window count indicates a number of packets that have been previously received at the node that should be compared against a received packet to determine whether a duplicate packet has been received. In one embodiment, a service level that has higher priority is assigned a lower look-back window count and thus examines fewer previously received packets than a service level having a lower priority. Such an arrangement reduces the possibility that traffic having higher priority is dropped as a security measure.

Shi-Hua Xiang, Boston, MA US

Patent application number

Description

Published

20090110690

Hiv Gp120 Crystal Structure and Its Use to Identify Immunogens - The present disclosure relates to stabilized forms of the HIV gp120 envelope protein in complex with the broadly neutralizing CD4-binding site antibody b12, to crystalline forms of the stabilized forms of the HIV gp120 envelope protein in complex with the broadly neutralizing CD4-binding site antibody b12, and to the high resolution structure obtained from these crystals by X-ray diffraction methods. Methods for identifying immunogenic polypeptides based on these structures are also disclosed.

CONFORMATIONALLY STABILIZED HIV ENVELOPE IMMUNOGENS - Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed.

02-09-2012

20120328641

CONFORMATIONALLY STABILIZED HIV ENVELOPE IMMUNOGENS - Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed.

12-27-2012

Shuanglin Xiang, Boston, MA US

Patent application number

Description

Published

20090123426

Compositions for Bacterial Mediated Gene Silencing and Methods of Using the Same - Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating cancer off cell proliferative disorders. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.

05-14-2009

20120093773

Compositions for Bacterial Mediated Gene Silencing and Methods of Using Same - Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating cancer of cell proliferative disorders. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.

04-19-2012

Tao Xiang, Worcester, MA US

Patent application number

Description

Published

20090202557

Compositions and methods for crystallizing antibody fragments - The invention provides methods of crystallizing antibodies and fragments thereof as well as crystals produced thereby. More particularly, the invention provides methods of crystallizing human and non-human Fab fragments of antibodies, either alone or as co-crystals with their target ligand. For example, a crystal comprising a murine Fab fragment of the antibody 125-2H or a human Fab fragment of the antibody ABT-325, which bind to IL-18, are provided as well as a co-crystal of a murine Fab fragment bound to IL-18. ABT-325 and 125-2H differ significantly in combining site character and architecture, thus explaining their ability to bind IL-18 simultaneously at distinct epitopes.

08-13-2009

Yibin Xiang, Waltham, MA US

Patent application number

Description

Published

20100261668

INHIBITORS OF S-ADENOSYL-L-METHIONINE DECARBOXYLASE - Novel mechanism-based inhibitors of S-adenosyl-L-methionine decarboxylase are provided. These compounds of formula (1) inhibit the life cycle of trypanosomes, and are useful to treat subjects infected with African trypanosomes. The invention includes pharmaceutical compositions and methods of using the compounds of formula (1).

10-14-2010

Yibin Xiang, Acton, MA US

Patent application number

Description

Published

20110184021

2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors - A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

07-28-2011

20110275673

INHIBITORS OF SPHINGOSINE KINASE 1 - The invention relates to compounds of Formula (I). Compounds of the present invention are inhibitors of sphingosine kinase 3, and are useful in the treatment of various disorders and conditions, such as inflammatory disorders.

Yibin Xiang, Dracut, MA US

Patent application number

Description

Published

20140255381

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS - The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.

09-11-2014

20140371460

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS - The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.